Literature DB >> 17107277

A historical sketch of the discovery and development of HIV-1 integrase inhibitors.

Andrea Savarino1.   

Abstract

The long process of HIV-1 integrase inhibitor discovery and development can be attributed to both the complexity of HIV-1 integration and poor 'integration' of these researches into mainstream investigations on antiretroviral therapy in the mid-1990s. Of note, some fungal extracts investigated during this period contain the beta-hydroxyketo group, later recognised to be a key structural requirement for keto-enol acids (also referred to as diketo acids) and other integrase inhibitors. This review reconstructs (in the general context of the history of AIDS research) the principal steps that led to the integrase inhibitors currently in clinical trials, and discusses possible future directions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107277     DOI: 10.1517/13543784.15.12.1507

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  24 in total

Review 1.  The importance of new companies for drug discovery: origins of a decade of new drugs.

Authors:  Robert Kneller
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 2.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

3.  New antiretroviral agents.

Authors:  Lawrence Siegel; Roy M Gulick
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

4.  New class of HIV-1 integrase (IN) inhibitors with a dual mode of action.

Authors:  Manuel Tsiang; Gregg S Jones; Anita Niedziela-Majka; Elaine Kan; Eric B Lansdon; Wayne Huang; Magdeleine Hung; Dharmaraj Samuel; Nikolai Novikov; Yili Xu; Michael Mitchell; Hongyan Guo; Kerim Babaoglu; Xiaohong Liu; Romas Geleziunas; Roman Sakowicz
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 5.  Novel targets for antiretroviral therapy: clinical progress to date.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor.

Authors:  Ying-Shan Han; Wei-Lie Xiao; Hongtao Xu; Victor G Kramer; Yudong Quan; Thibault Mesplède; Maureen Oliveira; Susan P Colby-Germinario; Han-Dong Sun; Mark A Wainberg
Journal:  Antivir Chem Chemother       Date:  2015-02

Review 7.  Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.

Authors:  Robert S Jansen; Kyu Y Rhee
Journal:  Trends Pharmacol Sci       Date:  2017-02-03       Impact factor: 14.819

8.  Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

Authors:  Mark G Lewis; Sandro Norelli; Matt Collins; Maria Letizia Barreca; Nunzio Iraci; Barbara Chirullo; Jake Yalley-Ogunro; Jack Greenhouse; Fausto Titti; Enrico Garaci; Andrea Savarino
Journal:  Retrovirology       Date:  2010-03-16       Impact factor: 4.602

9.  Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.

Authors:  Katty Terrazas-Aranda; Yven Van Herrewege; Daria Hazuda; Paul Lewi; Roberta Costi; Roberto Di Santo; Andrea Cara; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

Review 10.  Recent progress in antiretrovirals--lessons from resistance.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Drug Discov Today       Date:  2008-04-18       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.